Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
On this year's #WorldArthritisDay, we're proud to be partnering with @CaroWozniacki to bring #AdvantageHers to the chronic inflammatory disease community. Learn more below about the campaign and Caroline's own RA journey: https://t.co/33gbJ4P
— UCB News (@ucb_news) 12.10.2020 -
Chronic inflammatory diseases like rheumatoid arthritis affect 90M women worldwide - click below for helpful tips on managing these conditions, direct from @CaroWozniacki! #AdvantageHers #WorldArthritisDay https://t.co/33gbJ56QXW https://t.co/IWKpvxbeGC
— UCB News (@ucb_news) 11.10.2020 -
We were thrilled to have Prof. James F. Howard, Jr., Dr. Nicholas J. Silvestri and #MyastheniaGravis patient Kelly Davio join us for a virtual industry forum at #AANEM this morning. Special thanks to all who tuned in! https://t.co/RLAgyRVGpf
— UCB News (@ucb_news) 09.10.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
